The use of dendritic cells in cancer therapy
/in Dendritic Cells, International Publications /von 2001-06-01 / Lancet Oncol. 2001 Jun;2(6):343-53Dendritic cells for specific cancer immunotherapy
/in Dendritic Cells, International Publications /von 2001-04-01 / Biol. Chem. 2001 Apr;382(4):507-20Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
/in Dendritic Cells, Glioblastoma, International Publications /von 2001-02-01 / Cancer Res. 2001 Feb;61(3):842-7In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2001-01-01 / J. Cancer Res. Clin. Oncol. 2001;127(3):203-6Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2001-01-01 / Exp. Hematol. 2001 Jan;29(1):85-92Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2001-01-01 / Clin. Cancer Res. 2001 Jan;7(1):23-31Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report
/in Dendritic Cells, Glioblastoma, International Publications /von 2000-12-15 / Neurosurg Focus 2000 Dec;9(6):e8Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
/in Breast Cancer, Dendritic Cells, International Publications, Ovarian Cancer /von 2000-11-01 / Blood 2000 Nov;96(9):3102-8Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2000-03-01 / Br. J. Haematol. 2000 Mar;108(4):805-16
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution